Virios Therapeutics, Inc. stock is down -22.56% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 February’s closed higher than January.
Virios Therapeutics, Inc. focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!